Last reviewed · How we verify
anti-GPC3 CAR-T cells
anti-GPC3 CAR-T cells is a Biologic drug developed by Beijing Immunochina Medical Science & Technology Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | anti-GPC3 CAR-T cells |
|---|---|
| Sponsor | Beijing Immunochina Medical Science & Technology Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma (PHASE1)
- Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma (PHASE1)
- CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection (PHASE1)
- Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers (PHASE1)
- Clinical Study of Intratumoral Injection of CAR-T Cells in the Treatment of Advanced Liver Tumors (EARLY_PHASE1)
- Anti-GPC3 CAR T for Treating Patients With Advanced HCC (PHASE1)
- A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART) (PHASE1, PHASE2)
- Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- anti-GPC3 CAR-T cells CI brief — competitive landscape report
- anti-GPC3 CAR-T cells updates RSS · CI watch RSS
- Beijing Immunochina Medical Science & Technology Co., Ltd. portfolio CI
Frequently asked questions about anti-GPC3 CAR-T cells
What is anti-GPC3 CAR-T cells?
anti-GPC3 CAR-T cells is a Biologic drug developed by Beijing Immunochina Medical Science & Technology Co., Ltd..
Who makes anti-GPC3 CAR-T cells?
anti-GPC3 CAR-T cells is developed by Beijing Immunochina Medical Science & Technology Co., Ltd. (see full Beijing Immunochina Medical Science & Technology Co., Ltd. pipeline at /company/beijing-immunochina-medical-science-technology-co-ltd).
What development phase is anti-GPC3 CAR-T cells in?
anti-GPC3 CAR-T cells is in Phase 1.